Diagnosis and Treatment of Fulminant Myocarditis and Myopericarditis


About this study

If serum sST2 predicts heart failure (HF) in several cardiovascular disorders, in myocarditis patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Fulminant Myocarditis case definition: (Criteria 1, 2 AND 3, PLUS 1 or more of criteria 4, 5, OR 6 must be met):

  1. No evidence of significant valvular heart disease, congenital heart disease, or heart disease secondary to endocrine disorders
  2. Onset of heart failure symptoms < 2 weeks prior to diagnosis, requiring at least 1 inotrope or mechanical circulatory support
  3. If the patient is ≥40 years, coronary artery imaging by CT, MRI or invasive coronary angiography shows a maximum of one lesion ≥70% in severity
  4. EMB positive for borderline or active myocarditis per Dallas criteria.
  5. Cardiac MRI positive for myocarditis per Lake Louise criteria.
  6. LVEF <50% per cardiac imaging plus elevated troponin in the setting of a compatible clinical scenario

Exclusion Criteria:

  1. Patients who are being treated with immunosuppressive therapy at the time of the initial visit will be excluded from the study.
  2. Under the age of 18.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

DeLisa Fairweather, Ph.D.

Closed for enrollment

Contact information:

Damita Carryer R.N.

(507) 266-5179


More information


Publications are currently not available

Mayo Clinic Footer